Fortress Biotech Q3 Revenue Increases 20.5% Amid $28 Million Checkpoint Sale
ByAinvest
Friday, Nov 14, 2025 10:15 am ET1min read
FBIO--
Fortress Biotech reported Q3 revenue up 20.5% and a $28 mln sale of Checkpoint. The biopharmaceutical company has seven marketed prescription pharmaceutical products and over 25 programs in development. Its product candidates span six market areas, including oncology, rare diseases, and gene therapy.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet